French study to track endoscopic surgery for early esophageal cancer in 750 patients
NCT ID NCT07343869
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 750 adults in France who undergo endoscopic submucosal dissection (ESD) for early esophageal cancer or precancerous Barrett's esophagus. Researchers will track how well the procedure removes the cancer, how often it comes back, and whether additional treatments like surgery or chemotherapy improve outcomes. The goal is to provide real-world evidence to guide treatment decisions for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- endoscopic submucosal dissection (ESD)
- What this could lead to
- If successful, this study could help doctors better predict which patients need additional treatment after ESD, improving personalized care for early esophageal cancer.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove what works best. Results may vary across hospitals and patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BARRETTS ESOPHAGUS WITH DYSPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jules Verne Clinic
Nantes, 44300, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breath of life: new test could sniff out gut cancers before they spread
- Which biopsy method best spots early esophageal cancer?
- Battle of the scopes: which technique best wipes out Barrett's lesions?
- Cell sheet trial for esophageal cancer patients ends early with just one volunteer
- New drug targets tough esophageal cancer in early trial
- Exercise may help immune cells attack oesophageal tumors